| Metric | Value (₹ Cr) | vs Q3 FY25 |
|---|---|---|
| Revenue | 579.51 | 31.8% |
| Total Income | 589.11 | 31.2% |
| Expenditure | 470.31 | 24.7% |
| PBT | 118.80 | 65.8% |
| Net Profit | 88.27 | 63.9% |
| OPM | 27.19% | 25.98pp |
| NPM | 14.98% | 2.98pp |
| EPS | 4.24 | 46.7% |
Sai Life Sciences Reports Robust FY25 Results; Revenue Grows By 16%, Net Profit Up 105% Year-On-Year
14 May 2025 · 14 May 2025, 02:09 pm
Summary
Sai Life Sciences Limited, a Contract Research, Development and Manufacturing Organization (CRDMO), has announced its financial results for the quarter and year ended March 31, 2025. The company reported a 16% year-on-year growth in revenue from operations, a 42% increase in EBITDA, and a significant 105% increase in net profit for FY25. The Q4FY25 highlights include a 32% increase in revenue from operations and a 57% increase in net profit compared to Q4FY24.
Key Highlights
- 1
Revenue from Operations for FY25 was ₹ 16,950 Cr, a 16% increase from ₹ 1,465 Cr in FY24
- 2
EBITDA for FY25 stood at ₹ 425 Cr, a 42% increase from ₹ 300 Cr in FY24
- 3
PAT for FY25 was ₹ 170 Cr, a 105% increase from ₹ 83 Cr in FY24
- 4
Q4FY25 Revenue from Operations was ₹ 580 Cr, a 32% increase from ₹ 439 Cr in Q4FY24
- 5
Q4FY25 EBITDA was ₹ 161 Cr, a 30% increase from ₹ 124 Cr in Q4FY24
- 6
Q4FY25 PAT was ₹ 88 Cr, a 57% increase from ₹ 56 Cr in Q4FY24
Management Comments
Mr. Krishna Kanumuri
Managing Director and CEO, Sai Life Sciences Limited
We are pleased to report a strong performance for FY25, ably supported by solid execution, capacity expansion, and deeper engagement with our customers. Our integrated CRDMO model continues to add value, helping us deliver seamless solutions across the drug development lifecycle to our global and biotech partners. One of the highlights of the year was the launch of our Peptide Research Centre, set up to meet the growing demand for complex peptide synthesis and conjugation. This investment marks another step forward in strengthening our capabilities to support next-generation therapeutics. With India emerging as a strategic hub in global drug development, Sai Life Sciences is well-positioned to tap into new growth opportunities. We remain focused on investing in technology, infrastructure, and talent to stay aligned with the evolving needs of our clients. As we step into FY26, our priorities remain clear - to expand our capabilities, improve execution, and deliver lasting value to our stakeholders.
Mr. Siva Chittor
Director and Chief Financial Officer, Sai Life Sciences Limited
We are pleased to report a strong FY25 performance, driven by consistent momentum across our CDMO and CRO segments. Revenue grew by 16% and our EBITDA margin expanded to 25%, in line with our growth aspirations. Profit after tax grew by 105%, supported by stable finance costs and operating leverage. With the completion of our planned %720 Cr debt repayment, we have significantly strengthened our balance sheet and expect lower interest costs starting FY26. Capex for the year stood at = 408Cr, focused on enhancing our manufacturing footprint and expanding discovery capabilities.
Informational and educational content only. Not investment advice.